1 McElwee KJ, "What causes alopecia areata" 22 : 609-626, 2013
2 Picardo M, "Vitiligo" 1 : 15011-, 2015
3 Rork JF, "Understanding autoimmunity of vitiligo and alopecia areata" 28 : 463-469, 2016
4 Fröhlich E, "Thyroid autoimmunity : role of antithyroid antibodies in thyroid and extra-thyroidal diseases" 8 : 521-, 2017
5 Vrijman C, "The prevalence of thyroid disease in patients with vitiligo : a systematic review" 167 : 1224-1235, 2012
6 Taïeb A, "The definition and assessment of vitiligo : a consensus report of the Vitiligo European Task Force" 20 : 27-35, 2007
7 Miniati A, "Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin : relevance to early vitiligo" 39 : 54-57, 2014
8 Lee HT, "Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis" 37 : 45-52, 2010
9 Stinco G, "Serological screening for autoimmune polyendocrine syndromes in patients with vitiligo" 26 : 1041-1042, 2012
10 Speeckaert R, "S100B is a potential disease activity marker in nonsegmental vitiligo" 137 : 1445-1453, 2017
1 McElwee KJ, "What causes alopecia areata" 22 : 609-626, 2013
2 Picardo M, "Vitiligo" 1 : 15011-, 2015
3 Rork JF, "Understanding autoimmunity of vitiligo and alopecia areata" 28 : 463-469, 2016
4 Fröhlich E, "Thyroid autoimmunity : role of antithyroid antibodies in thyroid and extra-thyroidal diseases" 8 : 521-, 2017
5 Vrijman C, "The prevalence of thyroid disease in patients with vitiligo : a systematic review" 167 : 1224-1235, 2012
6 Taïeb A, "The definition and assessment of vitiligo : a consensus report of the Vitiligo European Task Force" 20 : 27-35, 2007
7 Miniati A, "Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin : relevance to early vitiligo" 39 : 54-57, 2014
8 Lee HT, "Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis" 37 : 45-52, 2010
9 Stinco G, "Serological screening for autoimmune polyendocrine syndromes in patients with vitiligo" 26 : 1041-1042, 2012
10 Speeckaert R, "S100B is a potential disease activity marker in nonsegmental vitiligo" 137 : 1445-1453, 2017
11 Rotondi M, "Role of chemokines in endocrine autoimmune diseases" 28 : 492-520, 2007
12 Liu M, "Rethinking screening for thyroid autoimmunity in vitiligo" 75 : 1278-1280, 2016
13 Li S, "Oxidative stress drives CD8+ T-cell skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes" 140 : 177-189, 2017
14 Spritz RA, "Novel vitiligo susceptibility loci on chromosomes 7(AIS2)and 8(AIS3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis" 74 : 188-191, 2004
15 Gilhar A, "Lymphocytes, neuropeptides, and genes involved in alopecia areata" 117 : 2019-2027, 2007
16 Richmond JM, "Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease" 137 : 350-358, 2017
17 Nanba T, "Increases of the Th1/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease" 19 : 495-501, 2009
18 Wang XX, "Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo" 174 : 1318-1326, 2016
19 Kim JY, "Impact of high-mobility group box 1 on melanocytic survival and its involvement in the pathogenesis of vitiligo" 176 : 1558-1568, 2017
20 Medici M, "Identification of novel genetic Loci associated with thyroid peroxidase antibodies and clinical thyroid disease" 10 : e1004123-, 2014
21 Lang KS, "HLA-A2 restricted, melanocyte-specific CD8(+)T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1" 116 : 891-897, 2001
22 Mockenhaupt M, "Evidence of involvement of CXC-chemokines in proliferation of cultivated human melanocytes" 12 : 597-601, 2003
23 Laberge G, "Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo" 18 : 300-305, 2005
24 Maouia A, "Differential expression of CXCL9, CXCL10, and IFN-γ in vitiligo and alopecia areata patients" 30 : 259-261, 2017
25 Gill L, "Comorbid autoimmune diseases in patients with vitiligo : a cross-sectional study" 74 : 295-302, 2016
26 Ferrari SM, "Circulating CXCL10 is increased in nonsegmental vitiligo, in presence or absence of autoimmune thyroiditis" 16 : 946-950, 2017
27 Harris JE, "Cellular stress and innate inflammation in organspecific autoimmunity : lessons learned from vitiligo" 269 : 11-25, 2016
28 Van Raemdonck K, "CXCR3 ligands in disease and therapy" 26 : 311-327, 2015
29 Wutte N, "CXCL13 and B-cell activating factor as putative biomarkers in systemic sclerosis" 169 : 723-725, 2013
30 Rashighi M, "CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo" 6 : 223-, 2014
31 Gey A, "Autoimmune thyroid disease in vitiligo : multivariate analysis indicates intricate pathomechanisms" 168 : 756-761, 2013
32 van den Boorn JG, "Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients" 129 : 2220-2232, 2009
33 Speeckaert R, "Alterations of CXCL12in serum of patients with vitiligo" 137 : 1586-1588, 2017
34 Xing L, "Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition" 20 : 1043-1049, 2014
35 Campbell JD, "Allergic humans are hyporesponsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop" 18 : 329-331, 2004